January 7, 2011 – The United States Patent and Trademark Office (USPTO) has granted an additional patent expanding protection of endothelial progenitor cell (EPC) capture technology. It applies to OrbusNeich’s Genous EPC technology.
The patent (U.S. Pat. No. US 7,803,183) covers a coating on an implantable medical device that has one or more layers of a matrix. Incorporated into the matrix are antibodies or antibody fragments that allow for capture in vivo of circulating EPCs.
Genous promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The antibody surface coating attracts EPCs circulating in the blood to form an endothelial layer that provides protection against thrombosis and modulates restenosis.
The technology will be used on a next-generation stent platform that combines luminal cell capture with abluminal drug elution and is currently in clinical trial evaluation
For more information: www.OrbusNeich.com